OBJECTIVES: This study was designed to identify patient preferences for different aspects of Crohn’s disease (CD) maintenance therapy for people with CD in Spain. METHODS: Main attributes of CD maintenance treatment were determined from a review of the literature and consultations with medical experts and patients. The discrete choice experiment included 5 attributes: type of drug administration, disease control, mild-to-moderate adverse events, serious adverse events and tumor incidence, plus a cost attribute in order to estimate willingness to pay (WTP) for improvements in attribute levels. A pilot study with 20 patients was carried forward to identify areas of misunderstanding. Two hundred and eight patients with a diagnosis of CD were presented with pairs of hypothetical treatment profiles with varied levels of adverse events, disease control, type of administration, tumor incidence and cost. Questions were also included to collect socio-demographic data. Data were analyzed using a random effects probit model. RESULTS: All attributes had the expected polarity and all were significant predictors of choice, except for the mild-to-moderate adverse events attribute, that was excluded from the analysis. Patients WTP were, €11,124/month for a reduction of a 10% in the probability of presenting a tumor, €227/month for a 10% reduction in the serious adverse events; and €211/month for an increase of a 10 % in the probability of obtaining a clinical response. Patients were also willing to pay €276/month and €223/month to have their treatment administered orally rather than with an injection or an infusion respectively. CONCLUSIONS:  Spanish CD patients have well-defined preferences among maintenance treatment attributes and are willing to accept tradeoffs among attributes. Participants indicated that they are willing to accept elevated serious adverse event risks but few risks of neoplasia in exchange for clinical efficacy. The perspective of the patients should be taken into account when making treatment decisions.